Repros Therapeutics Inc. (MM) News - RPRXD

- Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Filed...

Repros® Therapeutics Reports Outcome of Type B Meeting with FDA Regarding Androxal® in the Treatment of Secondary Hypogonadism

Repros Therapeutics Inc.® (NasdaqCM:RPRXD) today reported on the outcome of a Type B meeting held with the FDA to discuss two...

- Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Filed...

- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Repros® Has Regained Compliance with Nasdaq Continued Listing Requirements

Repros Therapeutics Inc.® (NasdaqCM:RPRXD) today announced that it has received a letter from Nasdaq confirming that the Company...

- Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report...

Repros® Therapeutics Begins Randomization of Subjects in Androxal® Type II Diabetes Phase II Trial

Repros Therapeutics Inc.® (NasdaqCM:RPRXD) today announced it has commenced randomization of subjects into its Phase II Androxal®...

- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

- Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Repros Therapeutics Inc. (MM) (RPRXD)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

RPRXD News

- Current report filing (8-K)

Repros® Therapeutics Reports Outcome of Type B Meeting with FDA Regarding Androxal® in the Treatment of Secondary Hypogonadism

- Current report filing (8-K)

- Statement of Changes in Beneficial Ownership (4)

- Statement of Changes in Beneficial Ownership (4)

Repros® Has Regained Compliance with Nasdaq Continued Listing Requirements

- Current report filing (8-K)

Repros® Therapeutics Begins Randomization of Subjects in Androxal® Type II Diabetes Phase II Trial

- Statement of Changes in Beneficial Ownership (4)

- Current report filing (8-K)

RPRXD Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Repros Therapeutics Inc. (MM) (RPRXD) News

Repros Therapeutics Inc. (MM) (RPRXD)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

RPRXD News

- Current report filing (8-K)

Repros® Therapeutics Reports Outcome of Type B Meeting with FDA Regarding Androxal® in the Treatment of Secondary Hypogonadism

- Current report filing (8-K)

- Statement of Changes in Beneficial Ownership (4)

- Statement of Changes in Beneficial Ownership (4)

Repros® Has Regained Compliance with Nasdaq Continued Listing Requirements

- Current report filing (8-K)

Repros® Therapeutics Begins Randomization of Subjects in Androxal® Type II Diabetes Phase II Trial

- Statement of Changes in Beneficial Ownership (4)

- Current report filing (8-K)

RPRXD Discussion

Your Recent History